Cyclobutane-1,3-diamine is a highly effective small-molecule scaffold, offering both conformational rigidity and optimized metabolic stability. Notably, Pfizer’s Abrocitinib, a cis-cyclobutane-1,3-diamine derivative, recently received FDA approval for treating atopic dermatitis (eczema). Over the past few years, our library of cyclobutane diamine compounds has expanded significantly, incorporating numerous spirocyclic structures to enhance the physicochemical properties.
Case study
Download SD files
Download PDF file
We offer
Over 100 cyclobutane 1,3-diamines from stock on 5-10 gram scale.
